immunity News and Research

RSS

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

In the recently published study in The Lancet, first-authored by Dr. Sue Ann Costa Clemens from the University of Oxford in the United Kingdom and the University of Siena in Italy, a comprehensive analysis has been pursued on the immunogenicity and safety of both homologous and heterologous boosting after receiving the inactivated vaccine CoronaVac.

26 Jan 2022

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Researchers assess the probability of T-cell apoptosis in patients with severe COVID-19 who were admitted to the hospital.

26 Jan 2022

Microbiome 'profiling' may help identify people at risk of long COVID

The make-up of the gut microbiome may be linked to a person's risk of developing 'long COVID' many months after initial infection with SARS-CoV-2, the virus responsible for COVID-19 infection, suggests research published online in the journal Gut.

26 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

New research on SARS-CoV-2 Omicron and care home residents

Researchers find a reduced risk of hospitalizations and deaths in long term care facility residents infected with SARS-CoV-2 Omicron variant.

26 Jan 2022

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

The Centers for Disease Control and Prevention reached out to pharmacists Wednesday to reinforce the message that people with moderate to severe immune suppression are eligible for fourth covid shots.

26 Jan 2022

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

In a new study, a team of researchers explored the association between total immunoglobulin (IgM, IgA, and IgG) against SARS-CoV-2 and protective immunity.

26 Jan 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Test-negative case-control analysis during a Delta variant-dominant period in California’s prisons

A new study studies the waning of vaccine-conferred protection against SARS-CoV-2 infection, specifically the Delta variant, in two high-risk populations.

26 Jan 2022

Understanding immune responses to SARS-CoV-2 infections in children

A study published in the journal Immunity analyzed the varied manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children.

26 Jan 2022

Serum biomarkers for SARS-CoV-2 reinfection identified in rhesus macaques

Many experts now predict that COVID-19, which so far has killed more than 5.5 million people worldwide, will remain endemic as new, infectious variants of SARS-CoV-2 emerge.

25 Jan 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

A new study assesses the effectiveness of two and three doses of the BNT162b2 vaccine against Omicron-related hospitalizations.

25 Jan 2022

Pharmacies are turning away immunocompromised patients seeking 4th covid shot

Patients with weakened immune systems — who are at high risk from covid-19 — say pharmacies are turning them away when they seek additional vaccine doses recommended by federal health officials.

25 Jan 2022

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

In a new study, a team of researchers reviewed the published literature to find evidence for humoral SARS-CoV-2 correlate of protection (CoP).

25 Jan 2022

Accelerating the COVID-19 booster vaccination rate to prevent Omicron variant hospitalizations and deaths

A new study investigates the impact of accelerating the pace of COVID-19 booster vaccination rates in the US in reducing COVID-19-related hospitalizations and mortalities.

25 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

immunity News and Research

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Microbiome 'profiling' may help identify people at risk of long COVID

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

New research on SARS-CoV-2 Omicron and care home residents

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

Test-negative case-control analysis during a Delta variant-dominant period in California’s prisons

Understanding immune responses to SARS-CoV-2 infections in children

Serum biomarkers for SARS-CoV-2 reinfection identified in rhesus macaques

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Pharmacies are turning away immunocompromised patients seeking 4th covid shot

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

Accelerating the COVID-19 booster vaccination rate to prevent Omicron variant hospitalizations and deaths

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News